Patients receiving chronic transfusion for aplastic anemia or hemoglobinopathy
are believed to be at high risk for developing red blood cell alloantibodies, while those
undergoing chemotherapy for leukemia are believed to be at low risk. To test this hypothesis,
we studied the acquisition of new alloantibodies in 703 transfused patients. While none of 99
patients with lymphocytic leukemia made new antibodies, patients with myelogenous leukemia
(16%), hemoglobinopathy (29%), aplastic anemia (11%), gastrointestinal bleeding
(11%) or renal failure (14%) made antibodies at statistically similar rates. Lymphocytic
leukemia or its treatment is characterized by a lack of immunologic response to transfusion.
Patients with hemoglobinopathy or aplastic anemia do not appear at statistically significant
greater risk of alloimmunization than many other patients requiring chronic transfusion.
Neither intensive chemotherapy for myelogenous leukemia nor the uremia of renal failure
significantly suppress the formation of blood group antibodies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.